Priti S. Hegde

33.2k citations

108 papers · 9.4k indexed · 6 hit papers · h-index 37

Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers 44
- Colorectal Cancer Treatments and Studies 20
Immunology top 0.5%
- Immunotherapy and Immune Responses 12
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 26
Pulmonary and Respiratory Medicine top 1%
- Ferroptosis and cancer prognosis 16
Hepatology top 2%
Surgery
- Bladder and Urothelial Cancer Treatments 15
Molecular Biology
- Angiogenesis and VEGF in Cancer 11
Pathology and Forensic Medicine
- Genetic factors in colorectal cancer 8

Co-authors: Daniel S. Chen Stefan Evers Vaios Karanikas Thomas Powles Gregg Fine Yohann Loriot Nicholas J. Vogelzang Daniel P. Petrylak
Cited by: Oncology Immunology Cancer Research
Journals: Journal of Clinical Oncology (25 papers)Cancer Research (11 papers)Journal for ImmunoTherapy of Cancer (8 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Priti S. Hegde

104 papers receiving 9.2k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Immunity
2020 PLoS ONE
2016 Journal of Clinical Oncology
2016 Clinical Cancer Research
2014 Nature
2000 BioTechniques

Peers

Countries citing papers authored by Priti S. Hegde

Since Specialization

Citations

This map shows the geographic impact of Priti S. Hegde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priti S. Hegde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priti S. Hegde more than expected).

Fields of papers citing papers by Priti S. Hegde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priti S. Hegde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priti S. Hegde. The network helps show where Priti S. Hegde may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Priti S. Hegde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Priti S. Hegde Line = papers co-authored together Priti S. Hegde links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Further delineation of defects in MRPS2 causing human OXPHOS deficiency and early developmental abnormalities in zebrafish European Journal of Human Genetics ·А А Щукин,慎一朗林田,Agnieszka Saran-Jagodzińska,孔陶,Andria Kowis,Aakanksha Anand,Priti S. Hegde,Н.Р. Бужинська,Raghavender Medishetti,容三島野,JIANG Lingbo,Jazmin C Wright,Shimeng Yan,Akhilesh Pandey,Joaquim Paulo de Lima Kaxinawa,Sanjiban Chakrabarty,Anju Shukla	2025	0
2	Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response JCO Precision Oncology ·Jay A. Moore,S. Alphonsa,Russell W. Madison,Justin Y. Newberg,Jörn Schwandt,A. Petris,Radwa Sharaf,Karthikeyan Murugesan,Bernard J. Fendler,Jason D. Hughes,Alexa B. Schrock,Priti S. Hegde,Geoffrey R. Oxnard,David Fabrizio,Garrett M. Frampton,Emmanuel S. Antonarakis,Ethan S. Sokol,Dexter X. Jin	2023	13
3	Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC. Journal of Clinical Oncology ·Christopher Sweeney,Ryon P. Graf,David Fabrizio,Kobe Yuen,Matthew Wongchenko,James A. Zacaruk,Priti S. Hegde,Geoffrey R. Oxnard,Thomas Powles	2023	1
4	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer Nature Communications ·Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Kimberly McGregor,Natalie Danziger,Dean C. Pavlick,Ole Gjoerup,Jeffrey S. Ross,Robert J. Harmon,Jon Chung,Brennan Decker,Lucas Dennis,Garrett M. Frampton,Luciana Molinero,Steffi Oesterreich,Jeffrey M. Venstrom,Geoffrey R. Oxnard,Priti S. Hegde,Ethan Sokol	2022	26
5	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients PLoS ONE ·Namrata S. Patil,Wei Zou,Simonetta Mocci,Alan Sandler,Marcus Ballinger,Susan Flynn,Marcin Kowanetz,Priti S. Hegde	2021	7
6	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer Nature Communications ·Mélanie Desbois,Akshata R. Udyavar,Lisa Ryner,Cleopatra Kozlowski,Yinghui Guan,Milena Dürrbaum,Shan Lu,Jean‐Philippe Fortin,Hartmut Koeppen,James Ziai,Ching‐Wei Chang,Shilpa Keerthivasan,Marie Plante,Richard Bourgon,Carlos Bais,Priti S. Hegde,Anneleen Daemen,Shannon J. Turley,Yulei Wang	2020	139
7	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Clinical Cancer Research ·Omid Hamid,Luciana Molinero,Christopher R. Bolen,Jeffrey A. Sosman,Eva Muñoz‐Couselo,Harriet M. Kluger,David F. McDermott,John D. Powderly,Indrani Sarkar,Marcus Ballinger,Marcella Fassò,Carol O’Hear,Daniel S. Chen,Priti S. Hegde,F. Stephen Hodi	2019	58
8	Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib Clinical Cancer Research ·Matthew Wongchenko,Grant A. McArthur,Brigitte Dréno,James Larkin,Paolo A. Ascierto,Jeffrey A. Sosman,Luc Andries,Mark Kockx,Stephen D. Hurst,Ivor Caro,Isabelle Rooney,Priti S. Hegde,Luciana Molinero,Huibin Yue,Ilsung Chang,Lukas C. Amler,Yibing Yan,Antoni Ribas	2017	28
9	Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study Annals of Oncology ·S. Gadgeel,Marcin Kowanetz,Wenbo Zou,Fred R. Hirsch,Keith M. Kerr,David R. Gandara,Fabrice Barlési,Abu Masykur,Mark L. McCleland,Hartmut Koeppen,M. Ballinger,A. Sandler,Priti S. Hegde,Achim Rittmeyer	2017	13
10	Reactive stroma mediates CD8+ T cell spatial distribution and function in ovarian cancer Annals of Oncology ·Masaru Tomita,Lisa Ryner,Ameya Udyavar,Mélanie Desbois,Cleopatra Kozlowski,Chien‐Wen Chang,Yinghui Guan,Shan Lu,Hartmut Koeppen,James Ziai,Richard Bourgon,Priti S. Hegde	2017	1
11	TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma Annals of Oncology ·Sanjeev Mariathasan,Shannon J. Turley,Dorothee Nickles,Alessandra Castiglioni,Kobe Yuen,黄扬 Huang Yang,Hiroyuki Kushibe,Elisabeth Koskinen,Jillian L. Astarita,Rafael Cubas,Suchit Jhunjhunwala,Yanling Yang,Yasin Şenbabaoğlu,V. Shablenko,Yohann Loriot,Ira Mellman,Beatriz Lavandera,Priti S. Hegde,Richard Bourgon,Tom Powles	2017	8
12	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial Journal of Clinical Oncology ·Thomas Sandmann,Richard Bourgon,Josep Garcia,Congfen Li,Timothy F. Cloughesy,Olivier Chinot,Wolfgang Wick,Ryo Nishikawa,Warren Mason,Roger Henriksson,Frank Saran,Albert Lai,N. Moore,Samir Kharbanda,Franklin Peale,Priti S. Hegde,Lauren E. Abrey,Heidi Phillips,Carlos Bais	2015	208
13	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Clinical Cancer Research ·Ravi Salgia,Premal H. Patel,John Bothos,Wei Yu,Steve Eppler,Priti S. Hegde,Shuang Bai,Surinder Kaur,Ihsan Nijem,Daniel V.T. Catenacci,Amy Peterson,Mark J. Ratain,Blasé N. Polite,Janice M. Mehnert,Rebecca A. Moss	2014	56
14	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors Molecular Cancer Therapeutics ·Elicia Penuel,Congfen Li,秀夫大津,Luciana Burton,Kyra J. Cowan,Mark Merchant,Robert L. Yauch,Premal H. Patel,Amy Peterson,Garret M. Hampton,Mark R. Lackner,Priti S. Hegde	2013	20
15	Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors Clinical Cancer Research ·Xin Yan,Jessica Li,Jenny Wu,G.A. Sedee,Colin D. Weekes,Amita Patnaik,Patricia LoRusso,Rainer K. Brachmann,Raymond K. Tong,Yibing Yan,Ryan J. Watts,Shuang Bai,Priti S. Hegde	2012	33
16	Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab Clinical Cancer Research ·Priti S. Hegde,Adrian M. Jubb,Bosibori Barake,I Czapska,Yong Meng,Coen Bernaards,Rebecca Elliott,Stefan Scherer,Daniel S. Chen	2012	152
17	Prostate cancer – a biomarker perspective Frontiers in Endocrinology ·Yanqiu Liu,Priti S. Hegde,Feng‐Min Zhang,Garret M. Hampton,Shidong Jia	2012	20
18	NF-κB Mediates the Stimulation of Cytokine and Chemokine Expression by Human Articular Chondrocytes in Response to Fibronectin Fragments The Journal of Immunology ·Judit I. Pulai,Hong Chen,Hee‐Jeong Im,Sanjay Kumar,Charles R. Hanning,Priti S. Hegde,Richard F. Loeser	2005	174
19	More than just innate immunity: comparative analysis ofChlamydophila pneumoniaeandChlamydia trachomatiseffects on host-cell gene regulation Cellular Microbiology ·Simone Heß,Jan Peters,Hans E. Meyer,Claudia Rheinheimer,Priti S. Hegde,Michal Magid-Slav,Ruth Tal‐Singer,Andreas Klos	2003	38
20	A concise guide to microarray analysis. BioTechniques ·Priti S. Hegde,Runnan Qi,Yacouba M. Chaibou,S. Dharap	2000	3

About Priti S. Hegde

Priti S. Hegde is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 108 papers that have together received 9.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (44 papers), Cancer Genomics and Diagnostics (26 papers), Colorectal Cancer Treatments and Studies (20 papers), Ferroptosis and cancer prognosis (16 papers), Bladder and Urothelial Cancer Treatments (15 papers), Immunotherapy and Immune Responses (12 papers), Angiogenesis and VEGF in Cancer (11 papers) and Genetic factors in colorectal cancer (8 papers). The work is most often cited by research in Oncology (5.6k citations), Immunology (2.8k citations) and Cancer Research (1.7k citations). Priti S. Hegde has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Daniel S. Chen, Stefan Evers, Vaios Karanikas, Thomas Powles, Gregg Fine, Yohann Loriot, Nicholas J. Vogelzang, Daniel P. Petrylak, Joaquim Bellmunt and Zachary Boyd. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact